Stoke Therapeutics, Inc.: late-stage zorevunersen for SCN1A Dravet Syndrome with durable 3-year data, Phase 3 EMPEROR and ...
Supply chain technology is entering a new phase in which AI, orchestration, automation, robotics, and risk management are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results